Vanguard Global Advisers
ADPT icon

Vanguard Global Advisers’s Adaptive Biotechnologies ADPT Stock Holding History

Vanguard Global Advisers’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.37M Sell
63,932
-240
-0.4% -$3.68K ﹤0.01% 1540
2026
Q1 		$891K Buy
+64,172
New +$1.02M ﹤0.01% 1718

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Global Advisers's ADPT Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Adaptive Biotechnologies (ADPT) stake by 0.37% in Q2 2026, selling an estimated $3.68K and leaving 63,932 shares worth $1.37M. The position accounts for ﹤0.01% of the portfolio, ranked #1540.

Vanguard Global Advisers first reported a position in ADPT in Q1 2026 and has held it in 2 quarters since. 299 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Vanguard Global Advisers held 63,932 shares of Adaptive Biotechnologies worth $1.37M as of Q2 2026.
  • Vanguard Global Advisers sold 240 Adaptive Biotechnologies shares in Q2 2026, an estimated $3.68K.
  • Adaptive Biotechnologies made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1540 holding.
  • Vanguard Global Advisers first reported a position in Adaptive Biotechnologies in Q1 2026 and has held it in 2 quarters since.
  • 299 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.